Thesis (Ph.D.)--University of Melbourne, The Walter and Eliza Hall Institute of Medical Research, The Division of Immunology and the Division of Molecular Medicine, Dept. of Medical Biology, Faculty of Medicine and Dentistry, 2009. / Typescript. Includes bibliographical references (p. 133-165)

A terapia celular representa uma abordagem promissora para o tratamento de cardiopatia isquêmica, porém aspectos-chave dessa estratégia permanecem incertos. Neste trabalho avaliamos a eficiência da retenção cardíaca de células da medula óssea marcadas com tecnécio (99m Tc-CMO) transplantadas, de acordo com o tempo após o infarto (1, 2, 3 e 7 dias) e a via de administração dessas células (intravenosa [IV], intraventricular [IC], intracoronariana [ICO] e intramiocárdica [IM]), em ratos submetidos à isquemia-reperfusão cardíaca [I&R]. Após 24 horas, a retenção cardíaca de 99m Tc-CMO foi maior na via IM comparada com a média alcançada pelas demais (6,79% do total injetado vs. 0,53%). O uso de fibrina como veículo para a injeção de células incrementou a retenção em 2.5 vezes (17,12 vs. 6,84%) na via IM. Curiosamente, quando administradas após 7 dias, a retenção de células na via IM alcançou valores próximos dos observados com da matriz de fibrina injetadas 24 h após a I&R (16,55 vs. 17,12%), enquanto que para as demais vias as mudanças foram insignificantes. Nos animais em que as CMO foram administradas por via intramiocárdica 24 horas após a I&R, com ou sem fibrina, observou-se melhora significante do desempenho cardíaco frente ao estresse farmacológico com fenilefrina quando comparados aos controles. Em conjunto, os dados mostram a biodistribuição das células injetadas após a I&R por 4 diferentes vias e 4 intervalos de tempo pós-lesão e indicam que a via IM é a que produz maior retenção cardíaca. O uso do biopolímero de fibrina aumenta a retenção das células e a eficácia deste efeito sobre a função cardíaca e mortalidade dos animais em longo prazo, além de 30 dias pós I&R, merecerá ser investigada no futuro. / Cell therapy represents a promising approach for ischemic cardiac disease, but key aspects of this strategy remain unclear. We examined the effects of timing and route of administration of bone marrow cells (BMCs) after myocardial ischemia/reperfusion injury (I&R). 99mTc-labeled BMCs were injected by 4 different routes: intravenous (IV), left ventricular cavity (LV), left ventricular cavity with temporal aorta occlusion (LV+) and intramyocardial (IM). The injections were performed 1, 2, 3, or 7 days after infarction. Cardiac retention was higher following the IM route compared to the average values obtained by all other routes (6.79% of the total radioactivity injected vs. 0.53%). Use of a fibrin biopolymer as vehicle during IM injection led to a 2.5-fold increase in cardiac cell accumulation (17.12 vs. 6.84%). Interestingly, the retention of cells administered with culture medium at day 7 post-MI by the IM route was similar to that observed when cells were injected 24 h post-IM using fibrin (16.55 vs 17.12%), whereas no significant changes were observed for the other routes. Cell therapy 24 hs post MI by IM injection, with or without fibrin, resulted in comparable improvement in cardiac function under pharmacological stress compared to control animals. Together, we provide evidence for the biodistribution of 99mTc-labeled BMCs injected post MI by 4 different routes and times post-injury, which shows that the IM rout is the most effective for cardiac cell retention. The use of a fibrin biopolymer further increased cardiac cell retention and its potential long term benefits, beyond 30, on reducing mortality and improving cardiac function deserve to be explored in the future.

Bone marrow mesenchymal stromal cells (BM MSCs) represent a heterogeneous population of progenitors with potential for generation of skeletal tissues. However the identity of BM MSC subpopulations is poorly defined mainly due to the absence of specific markers allowing in situ localization of those cells and isolation of pure cell types. Here, we aimed at characterization of surface markers in mouse BM MSCs and in their subsets with distinct differentiation potential. Using conditionally immortalized BM MSCs we performed a screening with 176 antibodies and high-throughput flow cytometry, and found 33 markers expressed in MSCs, and among them 3 were novel for MSCs and 13 have not been reported for MSCs from mice. Furthermore, we obtained clonally derived MSC subpopulations and identified bipotential progenitors capable for osteo- and adipogenic differentiation, as well as monopotential osteogenic and adipogenic clones, and thus confirmed heterogeneity of MSCs. We found that expression of CD200 was characteristic for the clones with osteogenic potential, whereas SSEA4 marked adipogenic progenitors lacking osteogenic capacity, and CD140a was expressed in adipogenic cells independently of their efficiency for osteogenesis. We confirmed our observations in cell sorting experiments and further investigated the expression of those markers during the course of differentiation. Thus, our findings provide to our knowledge the most comprehensive characterization of surface antigens expression in mouse BM MSCs to date, and suggest CD200, SSEA4 and CD140a as markers differentially expressed in distinct types of MSC progenitors.

Human cells from acute myeloid leukemia (AML) patients are frequently transplanted into immune-compromised mouse strains to provide an in vivo environment for studies on the biology of the disease. Since frequencies of leukemia re-initiating cells are low and a unique cell surface phenotype that includes all tumor re-initiating activity remains unknown, the underlying mechanisms leading to limitations in the xenotransplantation assay need to be understood and overcome to obtain robust engraftment of AML-containing samples. We report here that in the NSG xenotransplantation assay, the large majority of mononucleated cells from patients with AML fail to establish a reproducible myeloid engraftment despite high donor chimerism. Instead, donor-derived cells mainly consist of polyclonal disease-unrelated expanded co-transplanted human T lymphocytes that induce xenogeneic graft versus host disease and mask the engraftment of human AML in mice. Engraftment of mainly myeloid cell types can be enforced by the prevention of T cell expansion through the depletion of lymphocytes from the graft prior transplantation.

O enfisema pulmonar define-se como a destruição das paredes alveolares e consequente dispneia progressiva. Este trabalho objetivou a adequação de um modelo de transplante celular in vivo de BMMC em camundongos com enfisema pulmonar. O enfisema foi induzido por instilação nasal de elastase (4 UI por animal). O diâmetro alveolar médio para os grupos não tratados e tratados com elastase apresentou diferença estatisticamente significativa, e mudanças no padrão de expressão de metaloproteinases envolvidas no processo inflamatório foram detectadas, indicando que a instilação de uma dose de elastase promove lesão semelhante ao enfisema pulmonar. Infundiu-se 0,4ml de BMMC (7x106 céls./ml) nestes animais. No grupo tratado com células, detectou-se mudanças morfométricas e no padrão de expressão de metaloproteinases, indicando melhora na evolução da lesão pulmonar 21 dias após a infusão. Foram ainda avaliadas duas e três doses do pool de BMMC, porém os resultados das análises mostraram que não há diferenças entre estre grupos e os grupos controle. / Pulmonary emphysema is defined as the destruction of the alveolar walls and consequent progressive dyspnea. This study aimed the adequacy of a model of BMMC transplantation in vivo in mice with pulmonary emphysema. Emphysema was induced by nasal instillation of elastase (4 IU per animal). The mean linear intercept for the groups untreated and treated with elastase showed a statistically significant difference, and changes in the pattern of expression of metalloproteinases involved in inflammation were detected, indicating that the instillation of a dose of elastase promotes lung damage similar to emphysema. 0.4 ml of BMMC (7x106 céls. / ml) was infused in these animals. In the group treated with cells there were detected and morphometric changes in the pattern of expression of metalloproteinases, indicating an improvement in the evolution of lung injury 21 days after infusion. Were also evaluated two and three doses of the pool BMMC, but the results of the analysis showed no differences between experimental and the control groups.

A Doença Pulmonar Obstrutiva Crônica (DPOC) destaca-se como uma das doenças de maior prevalência, mortalidade e incapacitação. O principal fator de risco para a DPOC vincula-se à exposição a partículas e gases nocivos, sendo o tabagismo responsável pela maioria dos casos da doença. Apesar dos avanços terapêuticos, não há até o presente uma forma de tratamento eficaz. Neste contexto, as células-tronco representam uma prática terapêutica potencialmente promissora. Foi proposto, neste estudo, o uso de um modelo animal de enfisema pulmonar que busca mimetizar as condições patológicas de pacientes tabagistas, permitindo testar, in vivo, os efeitos terapêuticos das células-tronco. Os resultados obtidos demonstraram que os animais expostos à fumaça de cigarro desenvolveram os aspectos histomorfológicos da doença. A fluorescência direta revelou que as células infundidas migraram para os pulmões, esse achado, em concomitância com a recuperação pulmonar permitem sugerir que as células-tronco atuaram na regeneração do órgão. Consolidou-se, neste estudo, um novo aparato e uma metodologia que permitem avaliar novas terapias experimentais. Além disso, demonstrou-se a potencialidade terapêutica das células-tronco no tratamento do enfisema pulmonar. / Chronic Obstructive Pulmonary Disease (COPD) stands out as one of the most prevalent diseases, mortality and disability. The main risk factor for COPD is linked to exposure to noxious particles and gases, tobacco use is responsible for most cases of the disease. Despite therapeutic advances, there is no effective treatment. In this context, stem cells represent a potentially promising therapeutic practice. It was proposed in this study, using an animal model of emphysema that seeks to mimic the pathological conditions of smokers, allowing you to test, in vivo, the therapeutic effects of stem cells. The results showed that animals exposed to cigarette smoke developed the histopathological aspects of the disease. The direct fluorescence revealed that the infused cells migrated to the lungs, this finding, in tandem with the recovering lung may suggest that the stem cells worked in organ regeneration. Consolidated, in this study, a new apparatus and methodology for assessing new experimental therapies. Furthermore, it was demonstrated that the therapeutic potential of stem cells in the treatment of pulmonary emphysema.

Aggregatibacter actinomycetemcomitans está associado à periodontite agressiva, caracterizada pela intensa reabsorção do osso alveolar. Esta espécie produz a toxina distensora citoletal (AaCDT) que possui atividade de DNAse, e promove o bloqueio das células alvo na fase G2 ou G1/ G2. Por outro lado, CDT ativa a cascata apoptótica pela atividade de PIP3, regulando a proliferação e sobrevivência de linfócitos, pelo bloqueio de Akt. Em monócitos, AaCDT induz aumento da produção de citocinas pró-inflamatórias e inibe a produção de óxido nítrico e fagocitose. Células precursoras de osteoclastos têm origem hematopoiética e sofrem diferenciação em osteoclastos, mediada pelo RANKL, mas outros fatores co-estimulatórios estão envolvidos. A AaCDT induz a produção de RANKL por fibroblastos. Assim, formulamos a hipótese se CDT influenciaria a homeostase óssea por afetar a diferenciação de células precursoras de osteoclastos. O estudo visou determinar o efeito de AaCDT sobre a sobrevivência, diferenciação e atividade em RAW264.7 e BMC. Os dados sugerem que a CDT interfere na homeostase óssea, favorecendo a indução da diferenciação de células precursoras de osteoclastos e alterando o perfil de citocinas produzidas. / Aggregatibacter actinomycetemcomitans is associated with aggressive periodontitis, characterized by severe alveolar bone resorption. This species produces a distending toxin cytolethal (AaCDT) which has DNase activity, and promotes the blocking of target cells in G2 or G1 / G2 phase. On the other hand, CDT activates the apoptotic cascade by PIP3 activity, regulating lymphocyte proliferation and survival by blocking Akt. In monocytes, AaCDT enhances the production of proinflammatory cytokines and inhibits nitric oxide production and phagocytosis. Osteoclast precursor cells are of hematopoietic origin and must undergo differentiation into osteoclasts mediated by RANKL although other co-stimulatory factors are involved. AaCDT induces the production of RANKL by fibroblasts. Thus, CDT is hypothesized to influence bone homeostasis by affecting the differentiation of precursor cells into osteoclasts. This study aimed to determine the effect of AaCDT on survival, differentiation and activity of osteoclasts precursor cells. The data suggested that CDT interfere in bone homeostasis, favoring the differentiation of osteoclasts precursors cells and by altering their cytokines profile.

Dissertation (Ph.D.)--University of South Florida, 2007. / Title from PDF of title page. Document formatted into pages; contains 90 pages. Includes vita. Includes bibliographical references.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 6 uppsatser.

Dissertation (Ph.D.)--University of South Florida, 2007. / Includes vita. Includes bibliographical references (leaves 70-84). Also available online.